The biotech company was once widely regarded as one of the most dependable growth stocks on the ASX. But over the past few ...

Australian biotech giant CSL extended losses on Thursday, lingering near decade lows, after the U.S. military scrapped its ...

Carlisle Companies' Q1 sales performance reflects macroeconomic weakness but also a transitory headwind from harsh winter ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell short of the market’s revenue expectations in Q1 ...

CSL is near decade lows. Can it ever climb back? The post Can the beaten-down CSL share price ever reach $300 again? appeared ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Carlisle (CSL).

ASX companies are increasing manufacturing operations in the US offering resilience to tariffs and closer proximity to ...

Cochlear’s shock downgrade rattled the healthcare sector, with Scott Power warning structural headwinds are challenging the ...

This has got to be one of the craziest BMW M4 CSLs out there, and it came directly from Manhart's garage. Do you dig the ...

CSL shares hit a 9-year low as new demand concerns emerge. The post CSL's collapse deepens. Why this ASX giant can't find a ...

The Health Care (XHJ) industry inched 0.07% to close at 26154.0. CSL Ltd closed $52.80 below its 52-week high ($184.62), which the company achieved on Tuesday, January 27. Trading volume of 857,492 ...